Northpond Ventures and First Spark Ventures led a $73m Series A round in Walking Fish Therapeutics.

Northpond Ventures, a multi-billion dollar science-driven venture capital firm, and First Spark Ventures, a deep tech venture capital firm investing in scientists globally, led a $73m Series A round in Walking Fish Therapeutics, a company which is developing a platform to harness B cells' capability to activate the immune system in the treatment of cancer, with participation from Terra Magnum Capital Partners, Emerson Collective, Illumina Ventures, and Quan Capital. “Our team at Walking Fish welcomes Northpond Ventures and First Spark Ventures to an already world-class team of investors. Recent Walking Fish innovations in B cell engineering and manufacturing have enabled expansion of our pipeline to include new product opportunities. We believe strongly in the power of B cell therapeutics in applications spanning oncology to protein deficiency diseases, and we are confident the support of our new investors will enable us to further advance this emerging field of treatments,” Lewis Williams, Walking Fish Co-Founder and CEO.